IP Library Granted Patent US 9,901,556
Granted Patent B2
US 9,901,556 · App. 15/184,262 · Granted Feb 27, 2018

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Inventors: Michael Graeber (Lawrenceville, NJ); Janusz Czernielewski (Biot, FR)
Assignee: GALDERMA RESEARCH & DEVELOPMENT
A61K31/192A61K8/36A61K8/362A61K8/368A61K9/0014A61K9/06A61K9/08A61K31/07A61K47/02A61K47/06A61K47/10A61K47/14A61K47/183A61K47/22A61K47/26A61K47/32A61K47/34A61Q17/04A61Q19/007A61Q19/008A61K31/203A61K47/6903C07C2103/74C07C2603/74Y10S514/859
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,901,556
App. No.
15/184,262
Granted
Feb 27, 2018
Kind
B2
Abstract

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Claims (40)

1. A method for eliciting an early onset of action in regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises:

(1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof;

(2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol;

(3) water; and

(4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regultor, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent; a propyl paraben, and an antioxidant;

wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions, regression of non-inflammatory lesions or regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

2. The method according to claim 1 , wherein the common acne is of moderate to moderately severe intensity.

3. The method according to claim 1 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

4. The method according to claim 1 , wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

5. The method according to claim 1 , wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

6. A method for eliciting an early onset of action in regression of inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises:

(1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof;

(2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesguistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol;

(3) water; and

(4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant;

wherein said compositon is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by four weeks after treatment begins and is demonstrated by regression of inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

7. The method according to claim 6 , wherein the common acne is of moderate to moderately severe intensity.

8. The method according to claim 6 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

9. The method according to claim 6 , wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

10. The method according to claim 6 , wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

11. A method for eliciting en early onset of action in regression of non-inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises:

(1) 0.3% by weight of 6-[3-(1-adamantyl)-4-metaoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof;

(2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol;

(3) water; and

(4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant;

wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of non-inflammatory lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

12. The method according to claim 11 , wherein the common acne is of moderate to moderately severe intensity.

13. The method according to claim 11 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124 propylene glycol, sodium hyrdoxide and purified water.

14. The method according to claim 11 , wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

15. The method according to claim 11 , wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

16. A method for eliciting an early onset of action in regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises:

(1) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof;

(2) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934,PEG methyl glucose sesquistearate, PEG 400, methyl glucose sesquistearate, cyclomethicone, perhydrosqualene, glycerol, and phenoxyethanol;

(3) water; and

(4) at least one additive selected from the group consisting of a chelating agent, a preservative, a wetting agent, a pH regulator, an osmotic pressure modifier, an emulsifier, a UV-A screening agent, a UV-B screening agent, a propyl paraben, and an antioxidant;

wherein said composition is formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by four weeks after treatment begins and being demonstrated by regression of total acne lesions after four weeks of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after four weeks of treatment.

17. The method according to claim 16 , wherein the common acne is of moderate to moderately severe intensity.

18. The method according to claim 16 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124 propylene glycol, sodium hydroxide and purified water.

19. The method according to claim 16 , wherein the composition is a gel comprising adapalene, carbomer 934, disodium edetate, PEG methyl glucose sesquistearate, methyl glucose sesquistearate, glycerol, methyl paraben, cyclomethicone, perhydrosqualene, phenoxyethanol, propyl paraben, sodium hydroxide and purified water.

20. The method according to claim 16 , wherein the composition is a gel comprising adapalene, PEG 400 and ethanol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2016
From: GRAEBER, MICHAEL; CZERNIELEWSKI, JANUSZ
To: GALDERMA RESEARCH & DEVELOPMENT
Reel/Frame 038932/0285 →
Priority Claims (1)
FR 0203070 · Mar 12, 2002 · national
Continuity (8)
Continuation 14263758 · Apr 28, 2014
Continuation 13024681 · Feb 10, 2011
Continuation 12902972 · Oct 12, 2010
Continuation 12437008 · May 7, 2009
Continuation 10937612 · Sep 10, 2004
Continuation PCTEP0303246 · Mar 12, 2003
Provisional Application 60370223 · Apr 8, 2002
Related Publication 20170049732A1 · Feb 23, 2017